Hematopoietic cells are often obtained from bone marrow, peripheral blood and umbilical cord blood, albeit in very limited numbers. The ability to expand hematopoietic progenitor populations can be difficult to achieve.  A successful expansion must provide sufficient numbers of fully functional hematopoietic progenitor cells that are able to self-renew and differentiate into all functional blood cells.

造血细胞通常从骨髓、外周血和脐带血中获得，尽管数量非常有限。扩大造血祖细胞群的能力很难实现。成功的扩增必须提供足够数量的全功能造血祖细胞，这些细胞能够自我更新并分化为所有功能的血细胞。

• Manufactured under cGMP conditions
• Optimized to support vigorous expansion of hematopoietic progenitor cells while maintaining functionality
• Provides lot-to-lot consistency
• Maintains balanced lineage differentiation potential
• Manufactured to be scalable and facilitate transfer from research to clinic
• Drug Master File (DMF) registration
• Custom packaging and modifications available

Figure 1 CD34⁺ hematopoietic progenitor cells derived from human cord blood were cultured in PRIME-XV Hematopoietic Cell Basal XSFM or a commercially-available xeno-free expansion medium, both supplemented with a cocktail of cytokines (TPO, SCF, FLT-3L, IL-3 and IL-6). After 3, 7 and 9 days, the TNC (A) and fold expansion (B) of CD34⁺ cells were quantified.